-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Maintains Outperform on Nurix Therapeutics, Raises Price Target to $30

Benzinga·01/29/2026 16:03:44
Listen to the news
RBC Capital analyst Brian Abrahams maintains Nurix Therapeutics (NASDAQ:NRIX) with a Outperform and raises the price target from $28 to $30.